Profile data is unavailable for this security.
About the company
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.
- Revenue in USD (TTM)11.53bn
- Net income in USD733.00m
- Incorporated1931
- Employees50.00k
- LocationBaxter International Inc1 Baxter PkwyDEERFIELD 60015-4625United StatesUSA
- Phone+1 (847) 948-2000
- Fax+1 (302) 655-5049
- Websitehttps://www.baxter.com/
Mergers & acquisitions
Acquired company | BAX:NYQ since announced | Transaction value |
---|---|---|
Omnicell Inc | 2.92% | -- |